Phibro(PAHC) - 2026 Q1 - Quarterly Results

Financial Performance - Net sales increased by 40% to $363.9 million, up $103.5 million compared to the same period last year[3] - Adjusted EBITDA rose by $31.2 million to $61.9 million, reflecting strong operational performance[20] - Net income for the quarter was $26.5 million, an increase of $19.6 million compared to the same quarter last year[19] - Adjusted diluted EPS doubled to $0.73, an increase of $0.38 from the prior year[23] - Gross profit increased to $119.8 million, representing a 43% increase compared to $83.5 million in the prior year[36] - Operating income surged to $51.3 million, up from $17.7 million, marking a significant increase[36] - Adjusted EBITDA for the total company was $61.9 million, an increase of 102% from $30.7 million in the same period last year[38] - Adjusted net income was $29.8 million, compared to $14.1 million in the same period last year, indicating a strong performance[41] - The company reported a diluted adjusted net income per share of $0.73, up from $0.35[41] Segment Performance - Animal Health segment net sales grew by 55% to $283.5 million, driven by high demand for MFAs, nutritional specialties, and vaccines[5] - The Animal Health segment saw net sales of $283.5 million, a 55% increase from $182.5 million[38] Guidance and Projections - The company raised its fiscal year 2026 adjusted EBITDA guidance to between $230 million and $240 million, representing a 28% growth[27] - The updated fiscal year 2026 guidance includes net sales of $1.43 billion to $1.48 billion, indicating a 12% growth[27] Cash Flow and Tax - Free cash flow for the twelve months ended September 30, 2025, was $34.3 million[24] - The effective income tax rate for the quarter was 26.9%, slightly lower than the previous year's rate of 27.5%[15] - The effective tax rate for the period was 26.9%, slightly down from 27.5% in the previous year[36] Product Development - The company announced the national launch of Restoris™, a new dental gel for dogs, enhancing its product portfolio in companion animal oral health[2]